An index of frontier and emerging AI labs.
Bio / AI drug discovery
Public AI biologics company combining deep learning and synthetic biology to design therapeutic proteins and antibodies. NASDAQ:ABSI, roughly $800M market cap in May 2026.
| Name | Absci |
|---|---|
| Aliases | Absci Corporation, ABSI |
| Space | Bio / AI drug discovery |
| Founded | 2011 |
| Latest valuation | ~$800M (mkt cap)(confirmed) |
| Stage | — |
| Status | active |
| HQ | Vancouver, WA |
| Founders | Sean McClain |
| Website | https://www.absci.com |
| Careers | https://www.absci.com/careers |
| — | |
| X / Twitter | — |
| Date | Round | Amount ($M) | Valuation | Confidence | Source |
|---|---|---|---|---|---|
| — | — | — | ~$800M market cap | reported | — |
No founders recorded yet. Submit info.
| Date | Type | Title | Source |
|---|---|---|---|
| 2026-06-14 | added | Absci added to tracker Latest valuation: ~$800M market cap. | — |
No sources cited.
| Lab | Valuation | Founded |
|---|---|---|
| Isomorphic Labs | >$15B | 2021 |
| Xaira Therapeutics | ~$4B | 2024 |
| insitro | ~$2.5B | 2018 |
| Generate Biomedicines | ~$2B | 2018 |
| Recursion | ~$1.75B (mkt cap) | 2013 |
| Chai Discovery | $1.3B | 2024 |
| Earendil Labs | ~$1B | 2023 |
| EvolutionaryScale | >$1B | 2024 |